Quotient Limited (NASDAQ:QTNT) is reporting first quarter earnings results on Monday 3rd August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.33 per share from $ 8.67 million in revenue.
For the full year, analysts predict revenues of $ 36.00 million, while looking forward to loss of $ 1.34 per share.
Previous Quarter Performance
Quotient Limited posted loss for the fourth quarter of $ 0.31 per share, from the revenue of $ 8.70 million. The quarterly revenues up 5.07 percent compared with the same quarter last year. Wall street analysts are predicting, QTNT to report 4Q20 loss of $ 0.34 per share from revenue of $ 7.93 million. The bottom line results beat street analysts by $ 0.03 or 8.82 percent, at the same time, top line results outshined analysts by $ 0.77 million or 9.71 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Quotient Limited
Stock Performance
According to the previous trading day, closing price of QTNT was $ 7.84, representing a 226.67 % increase from the 52 week low of $ 2.40 and a 29.37 % decrease over the 52 week high of $ 11.10.
The company has a market capital of $ 631.96 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”QTNT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Quotient Limited will be hosting a conference call at 8:00 AM eastern time on 3rd August 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website quotientbd.com
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.
